Remdesivir for 5 or 10 days in patients with severe covid-19

New England Journal of Medicine

Volumn 383, Issue 19, 2020, Pages 1827-1837

  Goldman, Jason D ^a,b   Lye, David C B ^d   Hui, David S ^e   Marks, Kristen M ^f   Bruno, Raffaele ^g   Montejano, Rocio ⁱ   Spinner, Christoph D ^k   Galli, Massimo ^h   Ahn, Mi Young ^l   Nahass, Ronald G ^m,n   Chen, Yao Shen ^o   SenGupta, Devi ^p   Hyland, Robert H ^p   Osinusi, Anu O ^p   Cao, Huyen ^p   Blair, Christiana ^p   Wei, Xuelian ^p   Gaggar, Anuj ^p   Brainard, Diana M ^p   Towner, William J ^q   Muñoz, Jose ^j   Mullane, Kathleen M ^s   Marty, Francisco M ^t   Tashima, Karen T ^u   Diaz, George ^c   Subramanian, Aruna ^r   more..

^a Swedish Medical Center

^b UNIVERSITY OF WASHINGTON   (United States)

^c Providence Regional Medical Center   (United States)

^d TAN TOCK SENG HOSPITAL   (Singapore)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^f NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^g UNIVERSITY OF PAVIA   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j UNIVERSITY OF BARCELONA   (Spain)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l Seoul Metropolitan Seoul Medical Center   (South Korea)

^m ID Care   (United States)

ⁿ ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

^o KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^p GILEAD SCIENCES   (United States)

^q KAISER PERMANENTE   (United States)

^r STANFORD UNIVERSITY   (United States)

^s UNIVERSITY OF CHICAGO   (United States)

^t HARVARD MEDICAL SCHOOL   (United States)

^u BROWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; REMDESIVIR; ADENOSINE PHOSPHATE; ALANINE; ANTIVIRUS AGENT;

ACUTE KIDNEY FAILURE; ACUTE RESPIRATORY FAILURE; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMBIENT AIR; ARTICLE; ARTIFICIAL VENTILATION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CAUSE OF DEATH; CONSTIPATION; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; CREATININE CLEARANCE; DRUG SAFETY; DYSPNEA; EXTRACORPOREAL OXYGENATION; FEMALE; HOSPITALIZATION; HUMAN; HYPOKALEMIA; HYPOTENSION; HYPOXIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OXYGEN SATURATION; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PNEUMOTHORAX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SCORING SYSTEM; SEPTIC SHOCK; SIDE EFFECT; TREATMENT DURATION; TREND STUDY; VIRUS PNEUMONIA; BETACORONAVIRUS; CLINICAL TRIAL; COMPARATIVE STUDY; CORONAVIRUS INFECTION; DRUG ADMINISTRATION; MIDDLE AGED; MORTALITY; OXYGEN THERAPY; PANDEMIC; TREATMENT OUTCOME;

ADENOSINE MONOPHOSPHATE; ADULT; AGED; ALANINE; ANTIVIRAL AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OXYGEN INHALATION THERAPY; PANDEMICS; PNEUMONIA, VIRAL; TREATMENT OUTCOME;

EID: 85094950659     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa2015301     Document Type: Article

References (24)

1. Fauci AS, Lane HC, Redfield RR. Covid-19 — navigating the uncharted. N Engl J Med 2020;382:1268-9.
2. Abi-Habib M. Millions had risen out of poverty. Coronavirus is pulling them back. New York Times. April 30, 2020 (https://www.nytimes.com/2020/04/30/world/asia/coronavirus-poverty -unemployment.html).
3. Romm T. Mass layoffs begin in cities and states amid coronavirus fallout, threatening education, sanitation, health and safety. Washington Post. April 29, 2020 (https://www.washingtonpost.com/business/2020/04/29/cities-states-layoffs -furloughs-coronavirus/).
4. Spinelli A, Pellino G. COVID-19 pandemic: perspectives on an unfolding crisis. Br J Surg 2020 March 19 (Epub ahead of print).
5. Johns Hopkins Coronavirus Resource Center home page (https://coronavirus.jhu.edu/).
6. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases,in the US (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases -in-us.html).
7. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020 April 22 (Epub ahead of print).
8. Baden LR, Rubin EJ. Covid-19 — the search for effective therapy. N Engl J Med 2020;382:1851-2.
9. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382:1787-99.
10. de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci U S A 2020;117:6771-6.
11. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017;9:eaal3653.
12. Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.
13. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016;531:381-5.
14. Pizzorno A, Padey B, Julien T, et al. Characterization and treatment of SARSCoV-2 in nasal and bronchial human airway epithelia. April 2, 2020 (https://www.biorxiv.org/content/10.1101/2020.03.31 .017889v1). preprint.
15. Williamson BN, Feldmann F, Schwarz B, et al. Clinical benefit of remdesivir in rhesus macaques infected with SARSCoV-2. April 22, 2020 (https://www.biorxiv.org/content/10.1101/2020.04.15 .043166v2). preprint.
16. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30: 269-71.
17. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019;381:2293-303.
18. European Medicines Agency. Summary on compassionate use: remdesivir Gilead. April 3, 2020 (https://www.ema.europa.eu/documents/other/summary -compassionate-use-remdesivir-gilead _en.pdf).
19. World Health Organization. WHO R&D blueprint: novel coronavirus COVID-19 therapeutic trial synopsis (https://www.who.int/publications-detail/covid-19 -therapeutic-trial-synopsis).
20. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382: 1708-20.
21. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-78.
22. Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. Lancet 2020;395:1525-7.
23. Beigel JH. Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — preliminary report. N Engl J Med. DOI: 10.1056/NEJMoa2007764.
24. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5: 428-30.